Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Blood blood.2024025868.

https://doi.org/10.1182/blood.2024025868

Published: 2024

Includes: Supplemental data

Journal Articles

Mutations in BCOR , CCND2 , NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia

Christian Brieghel, Julie Dubois, Ida Kappel Buhl, Kazem Nasserinejad, Dennis De Rooij, Karl Nyrén, Hoa T Tran, Sabina Kersting, Mattias Mattsson, Juha Ranti, Rogier Mous, Gerrit Jan Veldhuis, Caspar da Cunha-Bang, Mark-David Levin, Valtteri Wirta, Richard Rosenquist, Arnon P. Kater, Carsten Utoft Niemann

Blood (2024) 144 (Supplement 1): 586.

https://doi.org/10.1182/blood-2024-204532

Published: 2024

Journal Articles

Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma

Febe Smits, Kazem Nasserinejad, Mark-David Levin, Gert Jan Timmers, Esther G.M. De Waal, Josien C Regelink, Gerjo A. Velders, Matthijs Westerman, Nazik Durdu-Rayman, Suzanne Last-Koopmans, Roel JW van Kampen, Claudia A M Stege, Kaz Groen, Maarten R. Seefat, Monique C. Minnema, Pieter Sonneveld, Paula F Ypma, Niels W.C.J. van de Donk, Sonja Zweegman

Blood (2024) 144 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2024-203477

Published: 2024

Journal Articles

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

Blood (2024) 144 (Supplement 1): 4739.

https://doi.org/10.1182/blood-2024-208754

Published: 2024

Journal Articles

Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax

Blood (2024) 144 (Supplement 1): 888.

https://doi.org/10.1182/blood-2024-211226

Published: 2024

Journal Articles

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Blood (2023) 142 (Supplement 1): 342.

https://doi.org/10.1182/blood-2023-180006

Published: 2023

Journal Articles

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Blood (2023) 142 (13): 1131–1142.

https://doi.org/10.1182/blood.2023020195

Published: 2023

Includes: Supplemental data

Journal Articles

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Niek Van Der Maas, Kazem Nasserinejad, Thomas Pabst, Johan A. Maertens, Dimitri A. Breems, Markus G Manz, Jacqueline Cloos, Gert J. Ossenkoppele, Yngvar Floisand, Patrycja Gradowska, Bob Lowenberg, Gerwin A. Huls, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen, Jurjen Versluis

Blood (2022) 140 (Supplement 1): 127–129.

https://doi.org/10.1182/blood-2022-158137

Published: 2022

Journal Articles

Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

Sabrin Tahri, Madelon M.E. de Jong, Cathelijne Fokkema, Natalie Papazian, Zoltan Kellermayer, Michael Vermeulen, Mark van Duin, Pieter van de Woestijne, Kazem Nasserinejad, Elona Saraci, Mattia D'Agostino, Francesca Gay, Vincent H.J. van der Velden, Niels WCJ Van De Donk, Annemiek Broijl, Pieter Sonneveld, Sonja Zweegman, Tom Cupedo

Blood (2022) 140 (Supplement 1): 9982–9984.

https://doi.org/10.1182/blood-2022-164812

Published: 2022

Journal Articles

Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 Trial

Blood (2021) 138 (Supplement 1): 69.

https://doi.org/10.1182/blood-2021-148630

Published: 2021

Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Blood (2021) 138 (Supplement 1): 80.

https://doi.org/10.1182/blood-2021-152112

Published: 2021

Journal Articles

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial

Pieter Sonneveld, Sonja Zweegman, Michele Cavo, Kazem Nasserinejad, Annemiek Broyl, Rosella Troia, Ludek Pour, Sandra Croockewit, Paolo Corradini, Gerard M.J. Bos, Ka Lung Wu, Jolanda Droogendijk, Monique C. Minnema, Mario Boccadoro

Blood (2021) 138 (Supplement 1): 1664.

https://doi.org/10.1182/blood-2021-149423

Published: 2021

Journal Articles

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

Blood (2021) 137 (8): 1117–1120.

https://doi.org/10.1182/blood.2020008608

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Blood (2019) 134 (Supplement_1): 695.

https://doi.org/10.1182/blood-2019-121694

Published: 2019

Journal Articles

Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials

Mark van Duin, Annemiek Broijl, Jasper Koenders, Sonja Zweegman, Monique C. Minnema, Francois G. Kavelaars, Remco Hoogenboezem, Kazem Nasserinejad, Mario Boccadoro, Peter Valk, PhD, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 1798.

https://doi.org/10.1182/blood-2019-130086

Published: 2019

Journal Articles

Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Marie José Kersten, MD PhD, Monique C. Minnema, Josephine M. Vos, MD PhD, Kazem Nasserinejad, Marcel Kap, BSc, Eftathios Kastritis, Maria Gavriatopoulou, MD, Martine E.D. Chamuleau, Dries Deeren, MD PhD, Lidwine Winnifred Tick, MD PhD, Jeanette K. Doorduijn, MD PhD, Fritz Offner, MD, Lara H Bohmer, MD, Karima Amaador, MD, Roberto D Liu, BSc, Steven T Pals, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 344.

https://doi.org/10.1182/blood-2019-122365

Published: 2019

Journal Articles

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Blood (2019) 134 (Supplement_1): 4292.

https://doi.org/10.1182/blood-2019-124377

Published: 2019

Journal Articles

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial

Pieter Sonneveld, MDPhD, Sonja Zweegman, MDPhD, Michele Cavo, MD, Kazem Nasserinejad, PhD, Rosella Troia, Ludek Pour, MD, Sandra Croockewit, MD, Paolo Corradini, MD, Francesca Patriarca, MD, Kalung Wu, MD, Jolanda Droogendijk, MD, Annemiek Broyl, MD PhD, Monique C Minnema, MD PhD, Bruno Costa, Karim Saad Iskander, MD, Mario Boccadoro, MD

Blood (2018) 132 (Supplement 1): 801.

https://doi.org/10.1182/blood-2018-99-114029

Published: 2018

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Noortje Thielen, MD PhD, Saskia K. Klein, MD PhD, Inge Ludwig, MD MSc, Matthijs Westerman, MD, Paula F Ypma, MDPhD, Yavuz Bilgin, MDPhD, Maaike Sohne, MD, Esther de Waal, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MDPhD, Sonja Zweegman, MDPhD

Blood (2018) 132 (Supplement 1): 596.

https://doi.org/10.1182/blood-2018-99-114668

Published: 2018

Journal Articles

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Saskia K. Klein, MD PhD, Esther de Waal, PhD, Corien Eeltink, Charlotte L.B.M. Korst, MD, Paula F Ypma, MDPhD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD, Bea Tanis, PhD, Monique C Minnema, MD PhD, Henk M.W. Verheul, MD PhD, Birgit I. Lissenberg-Witte, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MD PhD, Sonja Zweegman, MD PhD

Blood (2018) 132 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2018-99-116920

Published: 2018

NARROW

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Mutations in BCOR , CCND2 , NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia

Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 Trial

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials

Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only